ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the reti...
- Macular Degeneration
- Wet Macular Degeneration
- Choroidal Neovascularization
- Retinal Degeneration
- Retinal Diseases
- Eye Diseases
Age: 50 - 89 years
Gender: All